Many studies have shown that fibrosis of dystrophin deficient mdx skeletal muscles can be reduced through pharmacological myostatin inhibition [22,30,113,121,122], yet surprisingly, muscle quality (i.e., muscle:fat:fibrosis) was never assessed in any of the myostatin inhibitor clinical trials in DMD patients. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.